INSULIN THERAPY IN TYPE-2 DIABETIC SUBJECTS SUPPRESSES PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) ACTIVITY AND PROINSULIN-LIKE MOLECULES INDEPENDENTLY OF GLYCEMIC CONTROL

Eleven Type 2 diabetic subjects (10 male 1 female: age 56.2 +/- 9.7 (SD) yr) were treated in random order either with insulin or with sulphonylureas for 8 weeks each, without attempting to alter glycaemic control between the two treatment periods. Insulin treatment was associated with suppression of endogenous insulin secretion (fasting C-peptide levels -35.0 +/- 24.2 %; p =0.006), and of intact proinsulin (-43.1 +/- 36.8 %; p = 0.03) and 32,33 split proinsulin -20.1 +/- 27.0 %; p = 0.03). Activity of plasminogen activator inhibitor (PAI-1), a fast acting inhibitor of fibrinolysis, decreased significantly (-14.3 % +/- 27.5 %; p = 0.02) but no changes occurred in concentration of lipoproteins or apoproteins between therapies. Changes in concentrations of 32,33 split and intact proinsulin were closely and significantly related (r(s) = 0.83; p < 0.001) to each other but not with changes in concentrations of C-peptide (intact proinsulin r(s) = -0.41; p = 0.11) and 32,33 split proinsulin r(s) = -0.27; (p = 0.21). Percentage changes in intact proinsulin concentrations were positively correlated with those in PAI-1 (r(s) = 0.51; p = 0.05). There was, however a paradoxical negative relationship between changes in C-peptide concentrations and those of PAI-1 (r(s) = -0.73; p = 0.006). These preliminary observations suggest that insulin treatment in Type 2 diabetic subjects without any changes in glycaemic control is associated with a reduced activity of PAI-1, but is without effect on any other cardiovascular risk factors. Concentrations of insulin precursor molecules may play a role in determining fibrinolytic activity.